Logo image of FREQ

FREQUENCY THERAPEUTICS INC (FREQ) Stock Fundamental Analysis

USA - NASDAQ:FREQ - US35803L1089 - Common Stock

0.2996 USD
+0.02 (+5.94%)
Last: 11/3/2023, 8:00:00 PM
Fundamental Rating

2

Overall FREQ gets a fundamental rating of 2 out of 10. We evaluated FREQ against 531 industry peers in the Biotechnology industry. While FREQ seems to be doing ok healthwise, there are quite some concerns on its profitability. FREQ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FREQ had negative earnings in the past year.
In the past year FREQ has reported a negative cash flow from operations.
FREQ had negative earnings in each of the past 5 years.
In the past 5 years FREQ reported 4 times negative operating cash flow.
FREQ Yearly Net Income VS EBIT VS OCF VS FCFFREQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 0 20M -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -76.59%, FREQ is not doing good in the industry: 70.30% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -145.99%, FREQ is doing worse than 68.48% of the companies in the same industry.
Industry RankSector Rank
ROA -76.59%
ROE -145.99%
ROIC N/A
ROA(3y)-41%
ROA(5y)-34.99%
ROE(3y)-65.47%
ROE(5y)-52.09%
ROIC(3y)N/A
ROIC(5y)N/A
FREQ Yearly ROA, ROE, ROICFREQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FREQ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FREQ Yearly Profit, Operating, Gross MarginsFREQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

FREQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FREQ has more shares outstanding
The debt/assets ratio for FREQ is higher compared to a year ago.
FREQ Yearly Shares OutstandingFREQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
FREQ Yearly Total Debt VS Total AssetsFREQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.79, we must say that FREQ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FREQ (-5.79) is worse than 68.98% of its industry peers.
There is no outstanding debt for FREQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.79
ROIC/WACCN/A
WACC9.02%
FREQ Yearly LT Debt VS Equity VS FCFFREQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.14 indicates that FREQ has no problem at all paying its short term obligations.
FREQ has a worse Current ratio (3.14) than 68.48% of its industry peers.
A Quick Ratio of 3.14 indicates that FREQ has no problem at all paying its short term obligations.
FREQ's Quick ratio of 3.14 is on the low side compared to the rest of the industry. FREQ is outperformed by 67.66% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.14
FREQ Yearly Current Assets VS Current LiabilitesFREQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

FREQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.39%, which is quite good.
The Revenue for FREQ has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FREQ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.85%
EPS Next 2Y22.39%
EPS Next 3Y13.2%
EPS Next 5Y9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FREQ Yearly Revenue VS EstimatesFREQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2028 2029 2030 50M 100M 150M 200M 250M
FREQ Yearly EPS VS EstimatesFREQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FREQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FREQ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FREQ Price Earnings VS Forward Price EarningsFREQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FREQ Per share dataFREQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

FREQ's earnings are expected to grow with 13.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.39%
EPS Next 3Y13.2%

More info and screens

0

5. Dividend

5.1 Amount

FREQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FREQUENCY THERAPEUTICS INC

NASDAQ:FREQ (11/3/2023, 8:00:00 PM)

0.2996

+0.02 (+5.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-02 2023-11-02/bmo
Earnings (Next)03-08 2024-03-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners6.57%
Ins Owner Change0%
Market Cap11.06M
Revenue(TTM)N/A
Net Income(TTM)-77.74M
Analysts43.33
Price Target0.51 (70.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.2%
Min EPS beat(2)-28.23%
Max EPS beat(2)23.84%
EPS beat(4)3
Avg EPS beat(4)3.01%
Min EPS beat(4)-28.23%
Max EPS beat(4)23.84%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-87.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.99%
EPS NY rev (3m)3.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0
BVpS1.44
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.59%
ROE -145.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41%
ROA(5y)-34.99%
ROE(3y)-65.47%
ROE(5y)-52.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 3.14
Altman-Z -5.79
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)228.34%
Cap/Depr(5y)176.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.91%
EPS Next Y31.85%
EPS Next 2Y22.39%
EPS Next 3Y13.2%
EPS Next 5Y9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.23%
OCF growth 3YN/A
OCF growth 5YN/A

FREQUENCY THERAPEUTICS INC / FREQ FAQ

What is the ChartMill fundamental rating of FREQUENCY THERAPEUTICS INC (FREQ) stock?

ChartMill assigns a fundamental rating of 2 / 10 to FREQ.


Can you provide the valuation status for FREQUENCY THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to FREQUENCY THERAPEUTICS INC (FREQ). This can be considered as Overvalued.


How profitable is FREQUENCY THERAPEUTICS INC (FREQ) stock?

FREQUENCY THERAPEUTICS INC (FREQ) has a profitability rating of 0 / 10.


Can you provide the financial health for FREQ stock?

The financial health rating of FREQUENCY THERAPEUTICS INC (FREQ) is 5 / 10.